The impact of an infectious disease expert team on outpatient parenteral antimicrobial treatment in the Netherlands.
Administration, Intravenous
Administration, Oral
Adult
Aged
Aged, 80 and over
Ambulatory Care
/ methods
Anti-Infective Agents
/ administration & dosage
Communicable Diseases
/ diagnosis
Expert Testimony
/ methods
Female
Follow-Up Studies
Hospitals, Teaching
/ standards
Humans
Male
Middle Aged
Netherlands
/ epidemiology
Patient Care Team
/ standards
Patient Discharge
/ standards
Retrospective Studies
Treatment Outcome
Young Adult
Antimicrobial stewardship
Expert Consultation
Home treatment
Infectious diseases
OPAT
Outpatients
The Netherlands
Journal
International journal of clinical pharmacy
ISSN: 2210-7711
Titre abrégé: Int J Clin Pharm
Pays: Netherlands
ID NLM: 101554912
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
25
06
2018
accepted:
08
11
2018
pubmed:
28
11
2018
medline:
4
6
2019
entrez:
28
11
2018
Statut:
ppublish
Résumé
Background There is increasing interest in outpatient parenteral antimicrobial treatment. Objective To evaluate the added value of consultation of an infectious diseases expert team (consisting of two internist-infectious diseases specialists and a microbiologist) for advice regarding type, administration route and duration of antibiotic treatment. Setting A retrospective case series was performed at the Haga Teaching Hospital, a 700-bed regional teaching hospital in The Hague, The Netherlands. Methods Complication rate and mortality was evaluated during 60 days of follow-up. Therapeutic rationality regarding outpatient parenteral antimicrobial treatment was determined by presenting randomly selected paper cases from the database to two independent infectious diseases specialists who were blinded to patient's treatment and outcomes. The concordance between the two advices were analysed using Cohen's kappa. For those with discordance, an infectious diseases expert team meeting was organized to reach consensus. The final recommendation was compared to the actual given antibiotic treatment. Main outcome measure Discrepancy between the infectious disease expert team recommendations upon type, administration route and duration of antibiotics and the real outpatient parenteral antimicrobial treatment practice. Results Out of 89 included cases, 50 were randomly selected for review by the infectious diseases specialists. The kappa statistic regarding antimicrobial policy was 0.581 (P < 0.001). In 78% (39/50 cases), they had complete agreement upon all aspects of antibiotic treatment. The remaining 11 cases were reviewed by the expert team. Comparing the consensus of 50 cases to actual practice, in 14(28%) cases there was a discrepancy suggesting potential room for improvement. Comparing the cases in whom an individual infectious diseases specialist was involved in real practice to those cases without, there was 18% versus 42% discrepancy with the recommendations of the expert team (OR 3.4; 95% CI: 0.9-12.5, P = 0.06). Complication rate was 19% including unplanned readmissions and side effects of antimicrobial agent or administration route. Conclusion Though outpatient parenteral antimicrobial treatment policies in the Netherlands appear to be safe, consultation of an ID expert team, rather than an individual ID specialist, has the potential to optimize antimicrobial treatment in patients considered suitable for outpatient parenteral antimicrobial treatment.
Identifiants
pubmed: 30478489
doi: 10.1007/s11096-018-0751-4
pii: 10.1007/s11096-018-0751-4
pmc: PMC6394504
doi:
Substances chimiques
Anti-Infective Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
49-55Références
Clin Infect Dis. 2004 Jun 15;38(12):1651-72
pubmed: 15227610
Int J Antimicrob Agents. 2004 Nov;24(5):473-8
pubmed: 15519480
CMAJ. 2004 Nov 23;171(11):1369-73
pubmed: 15557592
Am J Med Sci. 2005 Aug;330(2):60-4
pubmed: 16103785
J Antimicrob Chemother. 2009 Dec;64(6):1316-24
pubmed: 19767623
Clin Infect Dis. 2010 Sep 15;51 Suppl 2:S198-208
pubmed: 20731577
Ann Pharmacother. 2011 Nov;45(11):1329-37
pubmed: 21990938
J Antimicrob Chemother. 2012 May;67(5):1053-62
pubmed: 22298347
Clin Infect Dis. 2013 Aug;57(3):419-24
pubmed: 23572486
Eur J Intern Med. 2013 Oct;24(7):617-23
pubmed: 23602223
Eur J Clin Microbiol Infect Dis. 2013 Nov;32(11):1465-70
pubmed: 23728737
Int J Antimicrob Agents. 2014 Jan;43(1):7-16
pubmed: 24200469
Clin Infect Dis. 2014 Mar;58(6):812-9
pubmed: 24357220
J Antimicrob Chemother. 2014 Jun;69(6):1695-700
pubmed: 24532684
J Pharm Pract. 2015 Oct;28(5):462-8
pubmed: 25107418
Infect Dis (Lond). 2015 Jan;47(1):39-45
pubmed: 25415655
J Antimicrob Chemother. 2015 Apr;70(4):965-70
pubmed: 25538169
Int J Antimicrob Agents. 2015 Sep;46(3):307-12
pubmed: 26233483
J Antimicrob Chemother. 2016 Oct;71(10):2980-7
pubmed: 27287237
J Pediatric Infect Dis Soc. 2018 May 15;7(2):e34-e36
pubmed: 28549165
Pediatrics. 1974 Sep;54(3):358-60
pubmed: 4213282
Epidemiology. 1996 Sep;7(5):561
pubmed: 8862998